Hodgkin lymphoma generally has a better prognosis than non-Hodgkin lymphoma, with an overall five-year survival rate of about 89% compared to roughly 74% for non-Hodgkin lymphoma. But “worse” is complicated here, because non-Hodgkin lymphoma isn’t one disease. It’s an umbrella term covering more than 60 subtypes, some of which are highly curable and others that are not. The answer depends heavily on which subtype of non-Hodgkin lymphoma you’re comparing.
Why Hodgkin Lymphoma Is Generally More Curable
Hodgkin lymphoma tends to behave in a more predictable way. It usually spreads in an orderly pattern from one group of lymph nodes to neighboring ones, which makes it easier to target with treatment. It also responds exceptionally well to chemotherapy. Around 80% or more of patients with classical Hodgkin lymphoma are considered cured after first-line treatment. Even among the roughly 25% of patients who relapse or don’t respond fully to initial therapy, about half can still achieve long-lasting remission with more intensive treatment.
Non-Hodgkin lymphoma, by contrast, is far less uniform. Some forms grow so slowly they may not need treatment for years. Others are among the most aggressive cancers known. This range means the “average” survival statistic for non-Hodgkin lymphoma blends together diseases with very different trajectories, pulling the overall number lower than Hodgkin lymphoma’s.
The Subtypes That Matter Most
Non-Hodgkin lymphoma falls into two broad categories: indolent (slow-growing) and aggressive (fast-growing). That distinction shapes nearly everything about how the disease behaves and how it’s treated.
Indolent subtypes include follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, and Waldenström macroglobulinemia. These grow so slowly that some patients are monitored without any treatment, sometimes for years. The tradeoff is that indolent lymphomas are often harder to cure completely. They can be managed for a long time, but they tend to come back.
Aggressive subtypes include diffuse large B-cell lymphoma (the single most common type of non-Hodgkin lymphoma) and Burkitt lymphoma. These require immediate treatment, but they also respond well to it. About 60% of patients with diffuse large B-cell lymphoma are cured. Burkitt lymphoma, while one of the fastest-growing cancers in humans, has high cure rates when treated aggressively, particularly in younger patients.
So a slow-growing non-Hodgkin lymphoma might never threaten your life but also never fully go away, while an aggressive one could be cured entirely or could prove fatal. Neither scenario maps neatly onto “better” or “worse” than Hodgkin lymphoma.
Who Gets Each Type
Non-Hodgkin lymphoma is far more common. It’s diagnosed at a rate of about 18.7 per 100,000 people per year, making it roughly eight to ten times more common than Hodgkin lymphoma. The median age at diagnosis for non-Hodgkin lymphoma is 68, meaning it primarily affects older adults. This older patient population partly explains the lower overall survival numbers, since older patients are less likely to tolerate intensive treatment.
Hodgkin lymphoma has an unusual age pattern. It peaks in young adults (ages 20 to 34) and again in adults over 55. Younger patients tend to tolerate treatment well and have excellent outcomes, which contributes to the high overall survival rate.
How Staging Works for Both
Both types use the same four-stage system. Stage I means cancer is in a single lymph node region. Stage II means two or more regions on the same side of the diaphragm (the muscle separating chest from abdomen). Stage III means regions on both sides of the diaphragm are involved. Stage IV means the cancer has spread to organs outside the lymphatic system, such as the liver, bone marrow, or lungs.
Each stage can also carry an “A” or “B” designation. “B” symptoms, which include unexplained fevers, drenching night sweats, and losing more than 10% of body weight within six months, signal a more active disease and typically indicate a worse prognosis. These B symptoms are especially significant in Hodgkin lymphoma staging.
For non-Hodgkin lymphoma, doctors also use a scoring system called the International Prognostic Index, which considers five factors: age over 60, advanced stage, elevated levels of a blood enzyme called LDH (a marker of how rapidly cells are turning over), poor physical functioning, and cancer in more than one site outside the lymph nodes. The more of these factors present, the more guarded the outlook.
Treatment and What to Expect
First-line treatment for Hodgkin lymphoma typically involves a chemotherapy combination known as ABVD, sometimes paired with radiation. This regimen is well-established and effective, with cure rates above 80%. More intensive chemotherapy regimens exist for higher-risk cases, though they come with a greater chance of side effects, including a small increased risk of developing a second cancer years later.
For the most common aggressive non-Hodgkin lymphoma (diffuse large B-cell), the standard approach combines chemotherapy with an antibody-based drug in a regimen called R-CHOP. This cures roughly 60% of patients. For indolent types, treatment might range from watchful waiting to chemotherapy combined with targeted therapies, depending on symptoms and how much the disease has progressed.
Both types of lymphoma have seen significant advances in treatment over the past two decades, particularly with immunotherapy approaches that train the body’s own immune cells to attack lymphoma cells. These newer options have improved outcomes for patients whose cancer returns after initial treatment.
Relapse and Long-Term Outlook
About 25% to 33% of Hodgkin lymphoma patients will either not respond fully to initial treatment or will relapse afterward. For those patients, more intensive chemotherapy followed by a stem cell transplant can produce lasting remission in about half of cases. That still leaves a meaningful number of patients with difficult-to-treat disease, but the overall picture remains favorable compared to most cancers.
Relapse patterns in non-Hodgkin lymphoma vary dramatically by subtype. Aggressive forms that are cured with initial treatment tend to stay gone. Indolent forms, however, commonly return after treatment, sometimes multiple times over many years. The disease can often be controlled with successive rounds of therapy, turning it into something more like a chronic condition than a single battle.
The bottom line: Hodgkin lymphoma is generally considered more curable and carries a better overall prognosis. But non-Hodgkin lymphoma isn’t automatically worse. Some of its subtypes are highly treatable, and others can be managed for decades. The specific subtype, stage at diagnosis, patient age, and overall health matter far more than the broad Hodgkin vs. non-Hodgkin label when predicting how any individual case will go.